Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 14 Triple Negative Breast Neoplasms 12 Carcinoma, Non-Small-Cell Lung 10 Esophageal Squamous Cell Carcinoma 9 Breast Neoplasms 8 Colorectal Neoplasms 7 Carcinoma, Renal Cell 7 Small Cell Lung Carcinoma 6 Neoplasms 6 Advanced Solid Tumor 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Head and Neck Neoplasms 5 Urinary Bladder Neoplasms 4 Recurrence 4 Carcinoma, Hepatocellular 4 Stomach Neoplasms 3 Solid Tumor 3 Neoplasm Metastasis 3 Liver Neoplasms 3 Carcinoma, Transitional Cell 3 Turcot syndrome 2 Sarcoma 2 Oropharyngeal Neoplasms 2 Nasopharyngeal Neoplasms 2 NSCLC 2 Muscle Invasive Bladder Cancer (MIBC) 2 Carcinoma, Squamous Cell 2 Biliary Tract Neoplasms 2 Advanced Solid Tumors 2

Interventions

Paclitaxel 69 Bevacizumab 62 Carboplatin 53 pembrolizumab 46 olaparib 32 Specimen Handling 27 Gemcitabine 27 Cyclophosphamide 26 Magnetic Resonance Spectroscopy 24 liposomal doxorubicin 22 Cisplatin 21 niraparib 20 Taxes 18 Nivolumab 18 fludarabine 17 Topotecan 17 Biopsy 17 Doxorubicin 14 Immunoglobulin G 12 Fulvestrant 12 Disulfides 12 Oxaliplatin 10 mirvetuximab soravtansine 9 durvalumab 9 aldesleukin 9 Surveys and Questionnaires 9 Ipilimumab 9 Fluorouracil 9 Blood Specimen Collection 9 cemiplimab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × toripalimab × 1 year × Clear all

NCT04918186 2026-05-12

IPROC

Canadian Cancer Trials Group

Phase 2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡